Pharmacogenetics — the science of how your genes affect how you respond to drugs — is gaining real traction in clinical practice. Spain's National Health System (NHS) has formalized this with its Common Catalog of Genetic and Genomic Tests (CGEN), which currently covers 12 pharmacogenetic markers tied to 22 drugs. Some testing is already mandatory before prescribing certain medications, like checking HLA-B*57:01 before abacavir or DPYD before fluoropyrimidines. But for many common drugs — statins, opioids, antidepressants, NSAIDs — routine pre-treatment genetic testing isn't yet standard practice.

The case for going proactive is strong. The landmark PREPARE trial, a multicenter European study of nearly 7,000 patients, found that a preemptive 12-gene pharmacogenetic panel reduced clinically relevant adverse drug reactions by roughly 30% in patients with actionable gene-drug interactions. Experts argue that storing genetic results in electronic health records (EHRs) once — and referencing them for future prescriptions — is both cost-effective and practical, especially for older adults on multiple medications.

Key Takeaways:

• Pre-emptive genotyping combined with EHR storage can guide future prescribing without the need for repeat testing
• Adults over 70 on polypharmacy have a ~90% probability of taking a drug covered by active pharmacogenomic guidelines
• Spain's CGEN is a starting point — meaningful gaps remain for statins, PPIs, opioids, and psychotropics
• Inconsistent EHR systems across regions remain a major barrier to broader implementation

Why it matters: Most adverse drug reactions are predictable — and preventable. As genetic testing becomes cheaper and more accessible, the real obstacle is integration: getting results into the right hands, at the right time, in a usable format. Closing that gap could meaningfully improve patient safety at scale.